ROARABLE
FREE $100K
My Trading Account β†’
β–Ύ
Trading Profile Active
Active Trader
Verified Trader
⚑ My $100K Trading Account β†’ β˜… My Saved Watchlist β†’
🟒 My $100K Account β†’ Today Screener Big Ideas Track Record πŸ’° $100K Arena 🎲 Predictions πŸ›οΈ Insiders 8 Analysts
Stock Ratings / Health Care / YDES
FLGT (31) BDSX (40) TLSI (30) XGN (36) ⌘ Pro Terminal β†’

YD Bio Limited (YDES) β€” RQD Stock Rating Cockpit

$5.97 +0.51% NASDAQ β€’ Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $5.96

YD Bio Limited (YDES) carries a Roarable Rating of D (Sell) with 44/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D β€’ SELL / AVOID Cap $420.7M
πŸ“€ Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚑ INSTANT AI QUANT PREVIEW β€’ $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on YDES Below β€” or Connect Your Own ChatGPT / Claude
πŸ€– Mara Quenwick β€’ AI Quant Lead (Click for Instant Brief) Is YDES stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
β–Ό

As of 2026-11-03, YD Bio Limited (NASDAQ: YDES) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 44/100 at a spot price of $5.97 (+0.51% 1D, market cap $420.7M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 9/20, SEC Balance-Sheet Forensics 14/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 3/20. Active quantitative signal LIQUIDITY_TAILWIND (BULLISH, conviction undefined/100) notes: undefined.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Ellis Vennor β€’ AI Peer & Flow Quant (Click for Instant Brief) How does YDES compare to FLGT and BDSX in the Health Care sector?
β–Ό

Within the Health Care sector (Medical Specialities), YDES carries a Roarable D (44/100 RQD), trailing P/E of N/A, gross margin of 28.1%, and ROIC of -20.0%. By comparison, FLGT (Fulgent Genetics Inc.) holds a E grade (31/100 RQD, P/E N/A, ROIC -6.8%, cap $567.4M) and BDSX (Biodesix Inc.) posts a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $245.4M). Among the 5-stock peer group, YDES leads on earnings multiple (N/A) while FLGT leads on capital efficiency (-6.8% ROIC).

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Gideon Ashmere β€’ AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for YDES?
β–Ό

Per YDES's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002011674), YD Bio Limited generated $596.8K in revenue (+16.9% YoY), -$8.3M in net income, and -$8.0M in free cash flow against $13.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists β€” not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
πŸ›‘οΈ Portfolio Crash X-Ray
EXT / AFTER-HRS: $5.96 (-0.10%)🧬 Dilution Drag (+2.48% YoY Shares)βš™οΈ Cash Engine: 8/20 (D-) β€’ 0% FCF Margin
Verify 90D Bucket Audit β†’
πŸ“Š Historical Track Record Warning: Scores below 50 (44/100 Β· D) historically underperformed SPY in 71% of rolling 90-day windows (-6.5% avg 90D alpha vs SPY β€’ 29.0% hit rate).
Audit Bucket Track Record β†’
RQD QUANT TACHOMETERSELL / AVOID β€’ D
025507510044
2-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) β€” not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw E Β· Rk C-
Cash (8)Whales (9)SEC (14)Macro (10)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-6.4% Base Target
$17 Bull$6 Base$4 Bear
πŸ“¬ FREE YDES RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: β€” (No Active Options Snapshot on file for YDES)Realized 20D OHLCV Swing Band: Β±12.5%
Deterministic 5-Pillar Attribution (44/100 Composite)
πŸ” WHY YDES SCORES 44/100 (D) β€” TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
β–² #1 Bullish Driver: SEC 10-K Forensic Risk+14/20 pts (32% of score)

Altman Z-Score 13.44 (FORTRESS SAFE (>3.0)) β€’ Piotroski F-Score 4/9

β–² #2 Bullish Driver: Macro Regime Fit+10/20 pts (23% of score)

FRED Regime Γ— Technicals: 30% of 52W Range β€’ RSI-14 at 52.3 (NEUTRAL RANGE)

β–Ό #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

πŸ“ˆ PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 β†’ Q2 β†’ Q3 β†’ Current
Q1 (-3Q)
52
Grade C-$6.10-4.3% Next Q
Q2 (-2Q)
49
Grade D$5.84+3.4% Next Q
Q3 (-1Q)
47
Grade D$6.04-1.2% Next Q
Current
44
Grade D$5.97-6.5% Hist 90D Ξ±
Trajectory: C- (52) β†’ D (44)Full Audit β†’
βš”οΈ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

βš”οΈ Adversarial Opposing Case: What Could Spark a YDES Turnaround Squeeze

Gideon Ashmere Forensic Desk β†’

While YDES currently carries a cautious 44/100 (D) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

πŸš€ Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

πŸš€ Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($5.17) and Max Pain ($6.27) forces dealer call-delta covering toward $16.51.

πŸš€ Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $YDESβ€’ $2.4M Crowd Pool β€’ Kalshi / Polymarket Composite
Contract: β€œYDES Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 44%NO 56%Trade / Inspect Odds β†’
RSI-14 MOMENTUMNEUTRAL RANGE
52.330 Oversold Β· 70 Hot
ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)
13.44>3.0 Fortress Safe
PIOTROSKI F-SCOREWEAK QUALITY (1–4)
4 / 99-Pt Accounting
52-WEEK LASER RANGE30% OF RANGE
L: $2$5.97H: $16
1. Money & Cash Health● WEAK
Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: D-RQD 8 / 20
2. Big Money & Insiders● TRIMMING
Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: ERQD 12 / 40
3. Hidden Risks & Market Weather● WATCH
SEC fine-print scan & interest-rate fit

No major SEC filing blowups, though current interest rates and Fed liquidity call for normal position sizing.

Factor Grade: C-RQD 24 / 40
MULTI-MODEL QUANT PANEL DELIBERATION

2-of-3 Quant Analysts Bearish Warning on YDES

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
BEARISH (40)

-20.0% ROIC with 28.1% gross margin and -1.93% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
BULLISH (70)

Altman-Z 13.44 and Piotroski 4/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BEARISH (37)

12/40 institutional & smart-money positioning score with 10/20 macro alignment.

Bull Case: Why Buyers Like YDES
  • βœ“Established market leader in Health Care with deep daily trading liquidity.
Bear Case: What Could Go Wrong
  • !Company executives have done more routine share selling than personal cash buying lately.
  • !Sensitive to high interest rates and tighter Federal Reserve market liquidity.
ON-DEMAND RQD QUANT WORKSHOP β€’ SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring YDES)

  • βœ“Walkthrough of YDES's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • βœ“3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • βœ“Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) β†’$100K Arena
YDES // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +18.92%β–² ASCENDING CHANNEL
2026-11-03O $5.87H $5.97L $5.87C $5.97VOL 47.4K
RES: $9.08SUP: $2.79SMA50: $5.17SMA200: $5.47
$12.24$9.38$6.53$3.67$0.81RES $9.08SUP $2.79$5.972026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

YDES Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

πŸ¦‹ YDES Butterfly Map β†’ + Track YDES β†’
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +16.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on YDES today. View full Setup Ledger β†’

πŸ¦‹ Documented & Second-Order Butterfly Connections Open Graph β†’

No direct multi-tier Butterfly edges indexed yet for YDES. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for YDES today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk β†’
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT β€’ SEC EDGAR XBRL Γ— RQD PEER BENCHMARK

πŸ“Š Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (YDES)

Health Care Rank #392 of 1015 βš”οΈ FLGT vs YDES Full Matrix β†’

1. Head-to-Head Health Care Peer Comparison (YDES vs. FLGT, BDSX, TLSI, XGN)

Industry: Medical Specialities (41 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, YD Bio Limited (YDES) ranks #392 by composite RQD confidence (44/100, grade D) and #466 by equity capitalization ($420.7M). Within this direct 5-issuer industry benchmark cohort, YDES leads on earnings valuation at N/A trailing P/E, while FLGT leads on capital efficiency and profitability with -6.8% ROIC and 40.6% gross margin. YDES currently leads its immediate peer cohort in composite quantitative strength at 44/100 (D).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
YDES ACTIVE
YD Bio Limited
D 44/100 β€” 28.1% -20.0% +0.51% $420.7M Benchmark Subject
FLGT
Fulgent Genetics Inc.
E 31/100 β€” 40.6% -6.8% -6.45% $567.4M /flgt-vs-ydes β†’
BDSX
Biodesix Inc.
D- 40/100 β€” β€” -35.0% -6.34% $245.4M /bdsx-vs-ydes β†’
TLSI
TriSalus Life Sciences Inc.
E 30/100 β€” 84.6% -35.0% -1.89% $227.8M /tlsi-vs-ydes β†’
XGN
Exagen Inc.
D- 36/100 β€” 58.3% -35.0% -2.33% $208.1M /xgn-vs-ydes β†’

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K β€’ FILED 2025-12-31 β€’ CIK 0002011674 β†—

In its most recent audited fiscal period (FY2025, filed 2025-12-31), YD Bio Limited (YDES) reported GAAP revenue of $596.8K (+16.9% vs. FY2024 revenue of $510.4K , and +70.5% cumulative change since FY2023) , GAAP net income of -$8.3M, operating cash flow of -$6.6M, and free cash flow of -$8.0M (-519.4% YoY). On the balance sheet, YDES closed FY2025 with $13.8M in total assets against $0 in total debt (Altman Z-Score: 13.44, Piotroski F-Score: 4/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $596.8K -$8.3M -$6.6M -$8.0M $13.8M β€”
FY2024 (FY) 2024-12-31 $510.4K -$1.4M -$1.2M -$1.3M $6.9M β€”
FY2023 (FY) 2023-12-31 $350.1K $13.6K -$55.7K -$55.7K β€” β€”

3. YDES Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

βœ“ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is YDES stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, YD Bio Limited (NASDAQ: YDES) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 44/100 at a spot price of $5.97 (+0.51% 1D, market cap $420.7M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 9/20, SEC Balance-Sheet Forensics 14/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 3/20. Active quantitative signal LIQUIDITY_TAILWIND (BULLISH, conviction undefined/100) notes: undefined.

How does YDES compare to FLGT and BDSX in the Health Care sector?

Within the Health Care sector (Medical Specialities), YDES carries a Roarable D (44/100 RQD), trailing P/E of N/A, gross margin of 28.1%, and ROIC of -20.0%. By comparison, FLGT (Fulgent Genetics Inc.) holds a E grade (31/100 RQD, P/E N/A, ROIC -6.8%, cap $567.4M) and BDSX (Biodesix Inc.) posts a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $245.4M). Among the 5-stock peer group, YDES leads on earnings multiple (N/A) while FLGT leads on capital efficiency (-6.8% ROIC).

What are the biggest fundamental strengths and SEC risk factors for YDES?

Per YDES's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002011674), YD Bio Limited generated $596.8K in revenue (+16.9% YoY), -$8.3M in net income, and -$8.0M in free cash flow against $13.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is YDES trading relative to its 50-day, 200-day, and 52-week technical levels?

YDES last traded at $5.97 (+0.51% on volume of 180,252 shares), positioning the stock +15.47% above its 50-day simple moving average ($5.17) and +9.14% above its 200-day simple moving average ($5.47). Across its 52-week range of $1.70 to $15.72, YDES sits at the 30.5% percentile with a 14-day RSI of 52.3 (NEUTRAL RANGE) and an implied next-earnings move of Β±12.5% ($5.22 to $6.72).

Direct Sub-Reports: YDES RQD Cockpit YDES 12M Forecast YDES Earnings & Move YDES Dividends & DRIP YDES Insiders & 13F YDES Whale Options YDES Profit Sankey YDES News & Why
ROARABLE RATING BRIEF β€’ RQD 44/100 (D) βœ“ SEC XBRL & RQD VERIFIED

YDES β€” YD Bio Limited: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

YD Bio Limited (YDES) earns a live Roarable RQD composite score of 44/100, corresponding to a D letter grade (Roarable Sell) at a spot price of $5.97 (+0.51% 1D, market capitalization $420.7M).

  • Fundamental Cash Engine (8/20): Anchored by return on invested capital (ROIC) of -20.0%, gross margin of 28.1%, operating margin of -60.0%, and free cash flow yield of -1.93%.
  • Whale 13F & Options Flow (9/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (10/20) + Forensic Balance Sheet (14/20): Incorporates a 1.00x equity beta, Altman Z-Score of 13.44, Piotroski F-Score of 4/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

. Per the recent news wire, the company has been associated with a no-blood-draw questionnaire for cancer risk assessment and a $10 AI cancer risk assessment tool. β€” describes its specific customer base or revenue model beyond these headlines. Reported revenue is small, at $0.6M for FY 2025, and the company operates at a negative operating margin of -60%.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), YD Bio Limited (YDES) reported $596.8K in annual revenue (up from $510.4K in FY2024, +16.9% YoY) and -$8.3M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($350.1K revenue, $13.6K net income) through FY2025, YDES scaled operating cash flow to -$6.6M and free cash flow to -$8.0M, backed by $13.8M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • πŸ‚ Primary Bull Case (D β€’ RQD 44/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -1.93% and institutional whale pillar of 9/20. With Fundamental Cash Engine at 8/20 and Institutional Whale Flow at 9/20, sustained execution supports upside toward the upper end of the $1.70 – $15.72 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Supply chain is NONE and butterfly links are empty. Upstream and downstream dependencies are β€” Sector correlation data is not provided beyond the Beta of 1.0 in the market data and the Roarable RQD rating's reference to sector sensitivity. The second-order items a prospective investor should watch are the cash burn trajectory (FCF of -$8.0M in FY 2025 against $6.0M cash) and whether the risk-watch cancer-screening product headlines translate into reported revenue, since reported revenue is currently under $1M.

  • Key Question #1: Can YDES sustain or expand its -60.0% operating margin and -20.0% ROIC against Medical Specialities peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $596.8K and free cash flow of -$8.0M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is YDES's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

YDES Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for YD Bio Limited (YDES) β€’ Click "Debate This Headline" to argue it in the Roar Pit below

πŸ’¬ Jump to YDES Debate Forum (3) ↓
πŸ”₯ THE ROAR PIT β€’ LIVE COMMUNITY DEBATE 3 Active Posts & Replies

YDES Bull vs. Bear Conversation Board β€” What's Your Call at $5.97?

πŸ‚ 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON YDES 🐻 33% BEARISH CONVICTION
1. Pick Your Side on YDES:
πŸ’‘ Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
SI SiliconVal_Bull RQD DEBATE OPENER β€’ Growth & Tech Investor πŸ‚ BULLISH 🎯 Target: $7.31 (+23.1%)
πŸ“Œ Pinned Debate

The Forensic Balance Sheet pillar scores 14 / 20 with Altman Z 13.44 and Debt/Equity 0.5, and cash rose to $6.0M in FY 2025.

The street is overcomplicating YD Bio Limited (YDES). The Forensic Balance Sheet pillar scores 14 / 20 with Altman Z 13.44 and Debt/Equity 0.5, and cash rose to $6.0M in FY 2025.. With an RQD score of 44/100 (D) and Forensic Balance Sheet at 14/20, any positive earnings surprise or guidance raise forces underweight funds to chase above $6.42.

ArenaChamp_24 πŸ‚ BULL

@ForensicBear Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Medical Specialities. If gross margin (28.1%) holds, EPS grows into the multiple faster than bears think.

FO ForensicBear RQD DEBATE OPENER β€’ 10-K Footnote Auditor 🐻 BEARISH 🎯 Target: $5.11 (-14.0%)
Spot @ $5.94

ROIC is -20%, FCF yield is -1.93%, and FY 2025 net loss of -$8.3M widened against $0.6M revenue, with insider conviction at 3 / 20.

Careful chasing YDES at $5.94. ROIC is -20%, FCF yield is -1.93%, and FY 2025 net loss of -$8.3M widened against $0.6M revenue, with insider conviction at 3 / 20.. Gross margin is 28.1%, but operating margin is -60.0%, which shows SG&A and reinvestment are eating into bottom-line EPS. Target $5.11 on multiple compression.

LIVE TAPE